NASDAQ:BYSIBeyondspring Stock Price, Forecast & News

Beyondspring's stock was trading at $11.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BYSI stock has increased by 52.3% and is now trading at $17.29. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beyondspring in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Beyondspring.

Beyondspring is scheduled to release its next quarterly earnings announcement on Wednesday, July 8th 2020. View our earnings forecast for Beyondspring.

Beyondspring Inc (NASDAQ:BYSI) posted its quarterly earnings data on Thursday, April, 30th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.09. View Beyondspring's earnings history.

4 Wall Street analysts have issued twelve-month target prices for Beyondspring's shares. Their forecasts range from $25.00 to $34.00. On average, they anticipate Beyondspring's stock price to reach $29.67 in the next year. This suggests a possible upside of 71.6% from the stock's current price. View analysts' price targets for Beyondspring.

News coverage about BYSI stock has trended negative this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Beyondspring earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the company's share price in the next few days. View the latest news aboutBeyondspring.

Some companies that are related to Beyondspring include SAGE Therapeutics (SAGE), Passage Bio (ZNTL), Epizyme (EPZM), Zymeworks (ZYME), Madrigal Pharmaceuticals (MDGL), Aurinia Pharmaceuticals (AUPH), Heron Therapeutics (HRTX), Xencor (XNCR), Zogenix (ZGNX), Theravance Biopharma (TBPH), Y-mAbs Therapeutics (YMAB), Corcept Therapeutics (CORT), Ironwood Pharmaceuticals (IRWD), Opko Health (OPK) and Constellation Pharmaceuticals (CNST). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Beyondspring investors own include Exelixis (EXEL), Enterprise Products Partners (EPD), Intel (INTC), AbbVie (ABBV), Gilead Sciences (GILD), Johnson & Johnson (JNJ), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), Crispr Therapeutics (CRSP) and Enbridge (ENB).

(BYSI) raised $4 million in an initial public offering on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO.

Beyondspring trades on the NASDAQ under the ticker symbol "BYSI."

Beyondspring's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.65%), State Street Corp (0.74%), Fosun International Ltd (0.56%), Geode Capital Management LLC (0.34%), Russell Investments Group Ltd. (0.13%) and Wells Fargo & Company MN (0.11%).

BYSI stock was sold by a variety of institutional investors in the last quarter, including Fosun International Ltd, Morgan Stanley, UBS Group AG, Deutsche Bank AG, and Federated Hermes Inc..

BYSI stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., BlackRock Inc., Geode Capital Management LLC, Alliancebernstein L.P., Rhumbline Advisers, State Street Corp, Wells Fargo & Company MN, and BNP Paribas Arbitrage SA.

Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BYSI stock can currently be purchased for approximately $17.29.

Beyondspring has a market capitalization of $482.15 million. The company earns $-38,080,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis.

The official website for Beyondspring is www.beyondspringpharma.com.

Beyondspring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 1-646-305-6387 or via email at [email protected]